SCHEMBL10085353

SCHEMBL10085353

CONC(=O)Nc1nc2c(s1)CN(c1cnc(OC)c(OC)c1)CC2

nearest known ligand 0.82

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 13/20 0.82
PIK3CD O00329 4/20 0.59
JAK2 O60674 1/20 0.55
NTRK1 P04629 1/20 0.44
PRKDC P78527 1/20 0.44
PIK3CA P42336 3/20 0.43
ALOX15 P16050 1/20 0.43
NPC1 O15118 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2D6 P10635 1/20 0.42
HPGD P15428 1/20 0.42
CYP2C19 P33261 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085343 0.90 PIK3CG (1.00) PIK3CGPIK3CDJAK2PIK3CAALOX15
SCHEMBL10085347 0.90 PIK3CG (0.78) PIK3CGPIK3CDJAK2NTRK1PRKDC
SCHEMBL10085423 0.88 PIK3CG (0.76) PIK3CGPIK3CDJAK2NTRK1PRKDC
SCHEMBL10085344 0.88 PIK3CG (0.75) PIK3CGPIK3CDJAK2NTRK1PRKDC
SCHEMBL10085429 0.86 PIK3CG (0.75) PIK3CGPIK3CDJAK2PIK3CA
SCHEMBL171917 0.85 PIK3CG (0.73) PIK3CGPIK3CDJAK2NTRK1PRKDC
SCHEMBL10085350 0.85 PIK3CG (0.75) PIK3CGPIK3CDJAK2NTRK1PRKDC
SCHEMBL10085349 0.83 PIK3CG (0.74) PIK3CGPIK3CDJAK2PIK3CA
SCHEMBL799298 0.83 PIK3CG (0.64) PIK3CGPIK3CDJAK2NTRK1PRKDC
SCHEMBL172096 0.82 PIK3CG (0.66) PIK3CGPIK3CDJAK2NTRK1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8524906-B2 Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-8524906-B2 Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-09-03 US disclosed
US-20120039849-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
US-20120039849-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-02-16 US disclosed
WO-2010096389-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120039849-A1 TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE PIK3CA, PIK3CD, PIK3CG PIK3CG 3/4885PIK3CD 2/4885JAK2 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.